Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) Operating Expenses (2020 - 2026)

Bioventus filings provide 6 years of Operating Expenses readings, the most recent being $85.8 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 4.8% to $85.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $326.1 million, a 8.82% decrease, with the full-year FY2025 number at $336.4 million, down 8.64% from a year prior.
  • Operating Expenses hit $85.8 million in Q4 2025 for Bioventus, up from $81.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.9 million in Q2 2024 to a low of $35.6 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $83.2 million (2022), compared with a mean of $82.0 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 162.76% in 2022 and later fell 18.69% in 2023.
  • Bioventus' Operating Expenses stood at $88.7 million in 2021, then fell by 0.76% to $88.0 million in 2022, then dropped by 7.33% to $81.5 million in 2023, then rose by 10.48% to $90.1 million in 2024, then dropped by 4.8% to $85.8 million in 2025.
  • The last three reported values for Operating Expenses were $85.8 million (Q4 2025), $81.6 million (Q3 2025), and $82.3 million (Q2 2025) per Business Quant data.